細胞治療市場規模、佔有率、成長分析、按治療類型、按細胞類型、按治療領域、按最終用戶、按地區 - 行業預測，2024-2031

2022年細胞治療市場規模為39億美元，預計將從2023年的67億美元成長到2031年的1,909.1億美元，預測期間（2024-2031年）複合年成長率為52%。

探索細胞療法的臨床試驗的激增正在推動細胞療法領域的顯著成長，並推動全球對研究和臨床應用的投資增加。這種快速成長得到了政府機構和商業組織持續資助的支持，促進了臨床試驗各階段的進展。同時，再生醫學的進步有望徹底改變慢性病的治療效果，美國和加拿大的先驅企業正在積極尋求利用新興的細胞療法市場的潛力。這些研究進展凸顯了更有效治療方法的有希望的途徑，並強調了這一發展領域中研究創新和商業機會之間的動態相互作用。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 成功的關鍵因素
• 競爭程度
• Start-Ups分析
• 監管分析
• 技術分析
• 主要投資機會
• 市場吸引力指數
• 市場生態系統
• 案例研究

細胞治療市場：按細胞類型

• 市場概況
• 幹細胞
• 非幹細胞

細胞治療市場：依治療類型

• 市場概況
• 同種異體療法
  • 幹細胞療法
    • 造血幹細胞治療
    • 間質幹細胞治療
    • 其他
  • 非幹細胞療法
    • 基於角質形成細胞和纖維母細胞的治療方法
    • 其他
• 自我治療
  • 幹細胞療法
    • BM
    • 血
    • 臍帶幹細胞
    • 脂肪來源的細胞
    • 其他
  • 非幹細胞療法
    • T細胞療法
    • CAR T細胞療法，
    • 基於 T 細胞受體 (TCR)
    • 其他
  • 其他

細胞治療市場：依技術分類

• 市場概況
• 細胞處理
• 細胞儲存、分配和處理
• 過程監控和品管

細胞治療市場：依治療領域

• 腫瘤學
• 心血管疾病（CVD）
• 肌肉骨骼疾病
• 皮膚科
• 其他

細胞治療市場：依最終用戶分類

• 市場概況
• 醫院/診所
• 學術研究所
• 其他

細胞治療市場：按地區分類的規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Thermo Fisher Scientific, Inc.（US）
• Merck KGaA（Germany）
• Danaher Corporation（US）
• Becton, Dickinson, and Company（US）
• Lonza Group（Switzerland）
• Sartorius AG（Germany）
• Nkarta, Inc.（US）
• Aurion Biotech（US）
• S. BIOMEDICS（Europe）
• MEDIPOST（South Korea）
• Anterogen Co., Ltd.（South Korea）
• JW Therapeutics（China）
• JCR Pharmaceuticals Co., Ltd.（Japan）
• Johnson & Johnson Services, Inc（US）
• Bristol-Myers Squibb Company（US）
• Gilead Sciences, Inc.（US）
• Novartis AG（Switzerland）
• Intellia Therapeutics（US）
• Iovance Therapeutics（US）
• CRISPR Therapeutics（Switzerland）

Cell Therapy Market size was valued at USD 3.9 Billion in 2022 and is poised to grow from USD 6.7 Billion in 2023 to USD 190.91 Billion by 2031, growing at a CAGR of 52 % during the forecast period (2024-2031).

The proliferation of clinical trials exploring cell-based therapies is fueling substantial growth within the cell therapy sector, prompting increased global investments in research and clinical applications. This surge is supported by continuous funding from governmental and commercial entities, facilitating advancements across various stages of clinical trials. Concurrently, progress in regenerative medicine is poised to revolutionize treatment efficacy for chronic diseases, with pioneering companies in the U.S. and Canada actively seeking to capitalize on the burgeoning market potential of cell therapy. These developments underscore a promising trajectory towards more effective therapeutic options and highlight the dynamic interplay between research innovation and commercial opportunity in this evolving field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cell Therapy Market Segmental Analysis

The Cell Therapy Market is segmented by cell type, therapy type, therapeutic area, end-user and region. Based on Cell Type, the market is segmented into Stem Cells (Bone Marrow, Blood, Umbilical Cord-Derived, Adipose-Derived Stem Cell, and Others (placenta, and nonspecific cells)), and Non-stem Cell. Based on Therapy Type, the market is segmented into Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies) Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others), and Autologous Therapies (Stem Cell Therapies (BM, Blood, & Umbilical Cord-derived Stem Cells, Adipose Derived Cells, Others) Non-Stem Cell Therapies (T-Cell Therapies, CAR T Cell Therapy, T Cell Receptor (TCR)-based, Others) and Others). Based on the Therapeutic Area, the market is segmented into Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology, and Others. Based on End Users, the market is segmented into Hospitals & Clinics, Academic & Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Cell Therapy Market

The need for innovative treatments targeting diseases such as cancer and cardiovascular disorders has spurred increased investment and research activity in cell-based approaches. This surge reflects a broader commitment to discovering and developing superior pharmaceuticals that can effectively combat these complex illnesses. The heightened demand for novel medicines has catalyzed extensive research initiatives and substantial financial backing specifically directed towards advancing cell-based research methodologies. These efforts aim to harness the potential of cellular mechanisms to create groundbreaking therapies, promising new avenues for treating and potentially curing some of the most challenging health conditions faced by humanity today.

Restraints in the Cell Therapy Market

In the past decade, despite significant technological advancements and continuous product development, the industry has faced persistent challenges due to a shortage of skilled personnel capable of operating complex devices like flow cytometers and multi-mode readers. This scarcity has impeded the sector's ability to fully leverage the latest technological innovations and achieve optimal operational efficiency. As these advanced instruments become more prevalent in research and industrial settings, the demand for proficient technicians and operators who can effectively utilize and maintain them continues to grow. Addressing this skills gap is crucial for organizations striving to maximize their technological investments and stay competitive in their respective fields.

Market Trends of the Cell Therapy Market

The cell therapy market has seen significant growth due to the increasing prevalence of chronic diseases, which are characterized as lasting a year or more and necessitating medical intervention that impacts daily life, according to the CDC. These conditions encompass heart disease, cancer, diabetes, and Parkinson's disease among others. Stem cell therapy offers potential benefits to patients suffering from various ailments such as spinal cord injuries, type 1 diabetes, Parkinson's disease, heart disease, cancer, and osteoarthritis.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Startup Analysis
• Regulatory Analysis
• Technology Analysis
• Top Investment Pockets
• Market Attractiveness Index
• Market Ecosystem
• Case Study

Cell Therapy Market by Cell Type

• Market Overview
• Stem Cell
• Non-stem Cell

Cell Therapy Market by Therapy Type

• Market Overview
• Allogeneic Therapies
  • Stem Cell Therapies
    • Hematopoietic Stem Cell Therapies
    • Mesenchymal Stem Cell Therapies
    • Others
  • Non-Stem Cell Therapies
    • Keratinocytes & Fibroblast-based Therapies,
    • Others
• Autologous Therapies
  • Stem Cell Therapies
    • BM
    • Blood
    • Umbilical Cord-derived Stem Cells
    • Adipose Derived Cells,
    • Others
  • Non-Stem Cell Therapies
    • T-Cell Therapies
    • CAR T Cell Therapy,
    • T Cell Receptor (TCR)-based
    • Others
  • Others

Cell Therapy Market by Technology

• Market Overview
• Cell Processing
• Cell Preservation, Distribution, And Handling
• Process Monitoring & Quality Control

Cell Therapy Market by Therapeutic Area

• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others

Cell Therapy Market by End User

• Market Overview
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Cell Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson, and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nkarta, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurion Biotech (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• S. BIOMEDICS (Europe)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MEDIPOST (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anterogen Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JW Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments